Feider Stephen 4
4 · Beta Bionics, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Feider Stephen
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-02$5.10/sh+20,000$102,000→ 62,614 total - Sale
Common Stock
2026-01-02$29.53/sh−20,000$590,680→ 42,614 total - Exercise/Conversion
Employee Stock Option (right to buy)
2026-01-02−20,000→ 49,695 totalExercise: $5.10Exp: 2033-09-13→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
- [F2]The weighted average sale price for the transaction reported was $29.534002 and the range of prices were between $29.09 and $30.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.